Antibodies for Coronavirus Disease 2019 (COVID-19) is under clinical development by Grifols and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Antibodies for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Antibodies for Coronavirus Disease 2019 (COVID-19) overview
Grifols overview
Grifols develops, produces, and markets plasma-derived medicines and transfusion medicines. The company is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering from rare, chronic and life-threatening infections. The company’s major products include essential plasma-derived medicines for treating conditions across various therapeutic areas such as neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.
For a complete picture of Antibodies for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.